172 related articles for article (PubMed ID: 25254965)
1. Galectin-3 as a marker and potential therapeutic target in breast cancer.
Zhang H; Luo M; Liang X; Wang D; Gu X; Duan C; Gu H; Chen G; Zhao X; Zhao Z; Liu C
PLoS One; 2014; 9(9):e103482. PubMed ID: 25254965
[TBL] [Abstract][Full Text] [Related]
2. Galectin-3 inhibition sensitizes human renal cell carcinoma cells to arsenic trioxide treatment.
Xu Y; Gu X; Gong M; Guo G; Han K; An R
Cancer Biol Ther; 2013 Oct; 14(10):897-906. PubMed ID: 23917726
[TBL] [Abstract][Full Text] [Related]
3. Arsenic induces functional re-expression of estrogen receptor α by demethylation of DNA in estrogen receptor-negative human breast cancer.
Du J; Zhou N; Liu H; Jiang F; Wang Y; Hu C; Qi H; Zhong C; Wang X; Li Z
PLoS One; 2012; 7(4):e35957. PubMed ID: 22558281
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-dependent regulation of PTEN after arsenic trioxide treatment in bladder cancer cell line T24.
Cao Y; Yu SL; Wang Y; Guo GY; Ding Q; An RH
Tumour Biol; 2011 Feb; 32(1):179-88. PubMed ID: 20857258
[TBL] [Abstract][Full Text] [Related]
5. Cotylenin A and arsenic trioxide cooperatively suppress cell proliferation and cell invasion activity in human breast cancer cells.
Kasukabe T; Okabe-Kado J; Kato N; Honma Y; Kumakura S
Int J Oncol; 2015 Feb; 46(2):841-8. PubMed ID: 25405645
[TBL] [Abstract][Full Text] [Related]
6. Melatonin promotes ATO-induced apoptosis in MCF-7 cells: Proposing novel therapeutic potential for breast cancer.
Nooshinfar E; Bashash D; Safaroghli-Azar A; Bayati S; Rezaei-Tavirani M; Ghaffari SH; Akbari ME
Biomed Pharmacother; 2016 Oct; 83():456-465. PubMed ID: 27427852
[TBL] [Abstract][Full Text] [Related]
7. Binding of galectin-1 to integrin β1 potentiates drug resistance by promoting survivin expression in breast cancer cells.
Nam K; Son SH; Oh S; Jeon D; Kim H; Noh DY; Kim S; Shin I
Oncotarget; 2017 May; 8(22):35804-35823. PubMed ID: 28415760
[TBL] [Abstract][Full Text] [Related]
8. Induction of the mesenchymal to epithelial transition by demethylation- activated microRNA-200c is involved in the anti-migration/invasion effects of arsenic trioxide on human breast cancer cells.
Si L; Jiang F; Li Y; Ye X; Mu J; Wang X; Ning S; Hu C; Li Z
Mol Carcinog; 2015 Sep; 54(9):859-69. PubMed ID: 24729530
[TBL] [Abstract][Full Text] [Related]
9. Arsenic trioxide induces autophagy and apoptosis in human glioma cells in vitro and in vivo through downregulation of survivin.
Chiu HW; Ho YS; Wang YJ
J Mol Med (Berl); 2011 Sep; 89(9):927-41. PubMed ID: 21594580
[TBL] [Abstract][Full Text] [Related]
10. Autocrine human growth hormone increases sensitivity of mammary carcinoma cell to arsenic trioxide-induced apoptosis.
Zekri A; Ghaffari SH; Yousefi M; Ghanizadeh-Vesali S; Mojarrad M; Alimoghaddam K; Ghavamzadeh A
Mol Cell Endocrinol; 2013 Sep; 377(1-2):84-92. PubMed ID: 23851143
[TBL] [Abstract][Full Text] [Related]
11. TG-interacting factor transcriptionally induced by AKT/FOXO3A is a negative regulator that antagonizes arsenic trioxide-induced cancer cell apoptosis.
Liu ZM; Tseng HY; Cheng YL; Yeh BW; Wu WJ; Huang HS
Toxicol Appl Pharmacol; 2015 May; 285(1):41-50. PubMed ID: 25791921
[TBL] [Abstract][Full Text] [Related]
12. Arsenic Trioxide Promotes Paclitaxel Cytotoxicity in Resistant Breast Cancer Cells.
Bakhshaiesh TO; Armat M; Shanehbandi D; Sharifi S; Baradaran B; Hejazi MS; Samadi N
Asian Pac J Cancer Prev; 2015; 16(13):5191-7. PubMed ID: 26225652
[TBL] [Abstract][Full Text] [Related]
13. Arsenic trioxide and breast cancer: analysis of the apoptotic, differentiative and immunomodulatory effects.
Baj G; Arnulfo A; Deaglio S; Mallone R; Vigone A; De Cesaris MG; Surico N; Malavasi F; Ferrero E
Breast Cancer Res Treat; 2002 May; 73(1):61-73. PubMed ID: 12083632
[TBL] [Abstract][Full Text] [Related]
14. LGALS3BP, lectin galactoside-binding soluble 3 binding protein, induces vascular endothelial growth factor in human breast cancer cells and promotes angiogenesis.
Piccolo E; Tinari N; Semeraro D; Traini S; Fichera I; Cumashi A; La Sorda R; Spinella F; Bagnato A; Lattanzio R; D'Egidio M; Di Risio A; Stampolidis P; Piantelli M; Natoli C; Ullrich A; Iacobelli S
J Mol Med (Berl); 2013 Jan; 91(1):83-94. PubMed ID: 22864925
[TBL] [Abstract][Full Text] [Related]
15. Lack of prognostic significance of survivin, survivin-deltaEx3, survivin-2B, galectin-3, bag-1, bax-alpha and MRP-1 mRNAs in breast cancer.
O'Driscoll L; Linehan R; M Kennedy S; Cronin D; Purcell R; Glynn S; W McDermott E; D Hill A; J O'Higgins N; Parkinson M; Clynes M
Cancer Lett; 2003 Nov; 201(2):225-36. PubMed ID: 14607338
[TBL] [Abstract][Full Text] [Related]
16. Arsenic trioxide overcomes rapamycin-induced feedback activation of AKT and ERK signaling to enhance the anti-tumor effects in breast cancer.
Guilbert C; Annis MG; Dong Z; Siegel PM; Miller WH; Mann KK
PLoS One; 2013; 8(12):e85995. PubMed ID: 24392034
[TBL] [Abstract][Full Text] [Related]
17. Suppression of TG-interacting factor sensitizes arsenic trioxide-induced apoptosis in human hepatocellular carcinoma cells.
Liu ZM; Tseng JT; Hong DY; Huang HS
Biochem J; 2011 Sep; 438(2):349-58. PubMed ID: 21649584
[TBL] [Abstract][Full Text] [Related]
18. Arsenic trioxide-induced growth arrest of breast cancer MCF-7 cells involving FOXO3a and IκB kinase β expression and localization.
Liu W; Gong Y; Li H; Jiang G; Zhan S; Liu H; Wu Y
Cancer Biother Radiopharm; 2012 Oct; 27(8):504-12. PubMed ID: 22988968
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of thymidylate synthase with arsenic trioxide in lung adenocarcinoma.
Lam SK; Mak JC; Zheng CY; Li YY; Kwong YL; Ho JC
Int J Oncol; 2014 Jun; 44(6):2093-102. PubMed ID: 24691991
[TBL] [Abstract][Full Text] [Related]
20. BIM-mediated AKT phosphorylation is a key modulator of arsenic trioxide-induced apoptosis in cisplatin-sensitive and -resistant ovarian cancer cells.
Yuan Z; Wang F; Zhao Z; Zhao X; Qiu J; Nie C; Wei Y
PLoS One; 2011; 6(5):e20586. PubMed ID: 21655183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
